#United States #healthcare #Biopharma #Emeryville #Eira Initiative

Exploring Global Biopharma Innovation through New Research

A recent series of working papers from the Berkeley Policy Institute's Eira Initiative has brought to light important insights into the factors that shape medical innovation worldwide. These findings were shared during the "Competing for the Cure" conference held in Paris at the end of October 2026.

The research focuses on key areas such as intellectual property rights, pricing policies, tax incentives, and regulatory frameworks, all of which significantly affect the development of new treatments. According to Bowman Heiden, co-director of the Eira Initiative, policymakers are faced with tough questions about improving access to medicines while maintaining the research that drives the creation of new therapies. He emphasizes that appropriate evidence is essential for navigating these complex decisions.

Highlights of the Research Findings

The Eira Initiative's latest papers delve into various critical subjects, offering data-driven insights:

1. Incentives for Rare Disease Research
Researchers Simona Gamba and Laura Magazzini discovered that the number of orphan drug designations in the U.S. significantly decreased following cuts to the federal Orphan Drug Tax Credit. This decline raises concerns about the future of rare disease treatment initiatives.

2. International Pricing Frameworks
In an analysis by Sandra Barbosu and Stephen Ezell, it was noted that U.S.-originated medicines received an average of 39 FDA approvals annually between 2020 and 2024, while only eight approvals were granted for European-origin medicines. The authors investigate how pricing policies contribute to this disparity, shedding light on the strategic advantages held by U.S. pharmaceutical companies.

3. Regulatory Reforms in China
Researchers Can Huang, Lina Lai, and Keyu Chen examined how streamlined drug review processes and alignment with international standards have enabled China to bolster its capacity for innovative drug development. This presents a significant shift in the global biopharma landscape as China's capabilities enhance competitiveness.

4. The Economics of Innovation
Alden Abbott and Satya Marar discussed how trade agreements and regulatory reforms might inspire more significant contributions from other wealthy nations towards U.S.-led pharmaceutical research. Their research indicates a need for cooperation to balance foreign pricing policies while keeping U.S. innovations incentivized.

5. Effects of Price Controls
Duane G. Schulthess and Harry P. Bowen reported troubling trends following the enactment of the Inflation Reduction Act, as they observed a decline in research for additional clinical uses of existing cancer treatments. Their findings also linked strict pricing policies in Europe with reduced venture capital investment and delays in patient access to new drugs.

Additional papers within this compilation address the impact of public health emergencies, the role of artificial intelligence, and the dynamics within India's biopharmaceutical sector on global research and development practices.

Future Directions

This research will be further explored in an upcoming publication titled "Competing for the Cure: Intellectual Property, Innovation Policy, and Competitiveness in Biopharmaceutical Ecosystems," edited by Jonathan Barnett, Bowman Heiden, and Margaret Kyle. In addition to establishing a foundational understanding of these issues, the goal is to furnish policymakers with the insights necessary to make informed and effective decisions that can ultimately enhance patient access and drive innovation in the biopharmaceutical industry.

The complete collection of the 2026 working papers is readily accessible for those interested in this crucial area of healthcare research.

About the Eira Initiative

The Eira Initiative operates under the umbrella of the Berkeley Policy Institute, focusing on providing policy research grounded in empirical data. By basing their work in factual analyses rather than narratives, the Initiative endeavors to create an informed dialogue about innovation policies pertinent to the biopharmaceutical, medical device, and life sciences sectors. To learn more, visit eirainitiative.org.